1. Home
  2. DOMO vs NKTX Comparison

DOMO vs NKTX Comparison

Compare DOMO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$8.28

Market Cap

477.0M

Sector

Technology

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$1.87

Market Cap

129.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMO
NKTX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
477.0M
129.3M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
DOMO
NKTX
Price
$8.28
$1.87
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$15.22
$13.25
AVG Volume (30 Days)
1.1M
641.1K
Earning Date
12-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$318,002,000.00
N/A
Revenue This Year
$2.28
N/A
Revenue Next Year
$2.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.01
$1.31
52 Week High
$18.49
$2.74

Technical Indicators

Market Signals
Indicator
DOMO
NKTX
Relative Strength Index (RSI) 30.40 52.06
Support Level $8.63 $1.79
Resistance Level $9.22 $1.90
Average True Range (ATR) 0.36 0.06
MACD 0.08 0.01
Stochastic Oscillator 1.98 82.50

Price Performance

Historical Comparison
DOMO
NKTX

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: